Skip to main content
TipRanks
Go Ultimate75% OFF

EssilorLuxottica SA (ESLOY) AI Stock Analysis

204 Followers
ESLOY

EssilorLuxottica SA

(Other OTC:ESLOY)

Select Model
Rating:70Outperform
Price Target:$107.00â–²(10.22% Upside)
Action:reiterated
Date:11/20/26

Strong financial performance and a notably positive earnings outlook are the main supports. Technical weakness and an elevated P/E ratio materially limit the score, producing a solid but not exceptional overall rating.

Positive Factors
Vertical integration and brand breadthEssilorLuxottica participates across product design, manufacturing, distribution, and direct retail, allowing it to capture economics at multiple stages of the eyewear value chain. Its proprietary and licensed brands also support broad consumer reach, premium positioning, and durable channel control.
Negative Factors
Rising leverageThe increase in debt relative to equity reduces financial flexibility compared with the prior year and raises sensitivity to interest rates. Although the balance sheet remains generally stable, a continued upward debt trajectory could constrain capital allocation and make downturns more difficult to absorb.

EssilorLuxottica SA (ESLOY) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%ESLOY-43.61%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$90.96B
Dividend Yield
2.34%
Average Volume (3M)
134.06K
Price to Earnings (P/E)
33.5
Beta (1Y)
0.79
Revenue Growth
15.30%
EPS Growth
10.92%
Country
US
Employees
203,791
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

EssilorLuxottica SA Business Overview & Revenue Model

Company Description

EssilorLuxottica S.A., established in Paris, France, in 1849, is a global enterprise dedicated to the design, production, and distribution of a wide range of ophthalmic products, including corrective lenses, eyewear frames, and sunglasses. The compan...

How the Company Makes Money

EssilorLuxottica makes money by selling eyewear and vision-care products and services through a vertically integrated model that spans manufacturing, wholesale distribution, and direct retail. Key revenue streams include: 1) Prescription lenses and l...

EssilorLuxottica SA Earnings Call Summary

Earnings Call Date:Jul 28, 2026(Q2-2026)|% Change Since:3.23%|Next Earnings Date:Feb 17, 2027
Earnings Call SentimentPositive

The call presented a predominately positive operational and financial picture: solid double-digit-like improvements in profitability metrics, strong free cash flow, robust regional momentum (notably Asia Pacific), and clear product and strategic progress in wearables, myopia management and medtech. Management acknowledged localized slowdowns (key accounts in North America, flat France, some EMEA licensing softness), currency and tariff timing uncertainties, and a demanding H2 comparison base. Overall the positives (revenue growth, margin recovery, record cash generation, product pipeline and strategic partnerships) materially outweigh the noted operational and timing risks.

Positive Updates

Solid Top-Line Growth
Group revenues +9.7% at constant currency (H1 2026) and +5.7% at current rates; Q2 revenue +8.7% at constant currency and +7.2% at current exchange rates, broadly aligned with medium-term guidance.

Negative Updates

Currency Headwinds and Exchange Variance
Current-rate growth lags constant-currency growth (H1: 5.7% vs 9.7%); U.S. dollar devalued ~2.5% against euro in Q2 causing a 1.5 ppt gap reduction but currency exposure remains a modeling risk and could affect H2 depending on FX moves.

Company Guidance

Management reiterated its medium‑term guidance of "solid revenue growth at constant currency," noting H1 revenues +9.7% cc (+5.7% reported) and Q2 +8.7% cc (+7.2% reported), while warning of a demanding H2 comparison but expressing confidence in delivering the financial ambition; by region Q2 was North America +7.2% cc, EMEA +8% cc, Asia‑Pacific +17% cc and Latin America +6.7% cc, with the core business up mid‑single‑digit and wearables nearly doubling in Q2 (analyst‑estimated contribution ≈4pp to Q2 growth). Profitability guidance pointed to gross profit accretion (+10bps), operating profit up 80bps at constant currency (50bps reported), net profit up 50bps cc (20bps reported) and operating expenses improving ~80bps of revenue despite continued R&D/medtech investments; free cash flow guidance is underpinned by €1.067bn generated in H1 (strongest in five years, >€100m ahead of prior year). Management also highlighted a net +60bps tariff benefit in H1 (with possible additional refunds in H2), a reduced constant/reported gap to 1.5pp after a ~2.5% USD devaluation in Q2 (potential H2 currency tailwind), and expects continued margin progression, controlled cost/inflation and revenue support from initiatives such as Stellest in ~11,000 US doors, myopia solutions (+25% in H1, >20% quarter‑on‑quarter), wearable rollouts and the Applied Materials partnership.

EssilorLuxottica SA Financial Statement Overview

Summary

Strong revenue growth, high structural margins, reliable cash generation, and a sound balance sheet support a solid score. Recent margin compression, modest capital efficiency, and higher leverage prevent a top-tier rating.

Income Statement

75Positive

Balance Sheet

70Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue29.47B28.49B26.51B25.39B24.49B19.82B
Gross Profit17.94B17.25B16.81B16.05B15.59B12.28B
EBITDA6.83B6.60B6.55B6.21B6.10B4.63B
Net Income2.52B2.22B2.36B2.29B2.15B1.45B
Balance Sheet
Total Assets65.03B63.87B64.26B60.52B60.56B59.41B
Cash, Cash Equivalents and Short-Term Investments1.93B3.54B2.25B2.56B1.96B3.29B
Total Debt15.31B14.40B13.22B11.66B12.20B13.02B
Total Liabilities25.12B24.39B23.26B21.63B22.41B23.54B
Stockholders Equity39.20B38.87B40.38B38.24B37.45B35.06B
Cash Flow
Free Cash Flow3.95B3.62B3.35B3.33B3.21B3.52B
Operating Cash Flow5.44B5.08B4.87B4.86B4.78B4.54B
Investing Cash Flow-2.94B-2.53B-3.62B-1.72B-2.62B-8.06B
Financing Cash Flow-3.29B-932.68M-1.65B-2.42B-3.58B-2.04B

EssilorLuxottica SA Technical Analysis

Technical Analysis SentimentNeutral
Last Price97.08

Price Trends

50DMA91.05Positive
100DMA92.89Positive
200DMA103.02Negative

Market Momentum

MACD2.09Positive
RSI47.95Neutral
STOCH2.66Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ESLOY, the sentiment is Neutral. The current price of 97.08 is below the 20-day moving average (MA) of 102.03, above the 50-day MA of 91.05, and below the 200-day MA of 103.02, indicating a neutral trend. The MACD of 2.09 indicates Positive momentum. The RSI at 47.95 is Neutral, neither overbought nor oversold. The STOCH value of 2.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ESLOY.

EssilorLuxottica SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ESLOY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ESLOYESLOY70Outperform$91.84B33.486.39%2.34%15.30%10.92%
BLCOBLCO65Neutral$7.49B-67.65-1.73%―8.88%63.73%
COOCOO63Neutral$11.55B20.736.88%―4.73%43.89%
STAASTAA59Neutral$1.27B2535.000.15%―42.36%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
POCIPOCI49Neutral$45.85M-14.09-14.10%―52.97%65.02%
LUCYLUCY31Underperform$6.37M-0.59-102.66%―56.89%52.61%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%ESLOYCOOSTAAPOCIBLCOLUCYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ESLOY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ESLOYEssilorluxottica (OTC)97.08-75.95-43.89%
COOCooper Companies60.33-15.14-20.06%
STAAStaar Surgical Company25.03-2.97-10.61%
POCIPrecision Optics Corporation, Inc.4.07-0.53-11.52%
BLCOBausch + Lomb Corporation20.695.6237.29%
LUCYInnovative Eyewear, Inc.0.70-0.86-54.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026